^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Depocyte (liposomal cytarabine)

    Associations

    News

    Trials
    Company:
    Leadiant Biosci, Mundipharma
    Drug class:
    DNA polymerase inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    NCI-2022-03803: A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts (clinicaltrials.gov)
    P2, N=60, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2025 --> Dec 2025
    Trial completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • cladribine • Depocyte (liposomal cytarabine)
    4ms
    IELSG30: Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis (clinicaltrials.gov)
    P2, N=54, Completed, International Extranodal Lymphoma Study Group (IELSG) | Active, not recruiting --> Completed
    Trial completion
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Depocyte (liposomal cytarabine)
    6ms
    A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias (clinicaltrials.gov)
    P1, N=22, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    sorafenib • cytarabine • decitabine • cladribine • Depocyte (liposomal cytarabine)
    7ms
    Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=26, Completed, Medical College of Wisconsin | Active, not recruiting --> Completed | Trial completion date: Oct 2024 --> May 2024
    Trial completion • Trial completion date • Combination therapy
    |
    cytarabine • mitoxantrone • Actimab-A (lintuzumab-Ac225) • Depocyte (liposomal cytarabine)
    8ms
    Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=41, Completed, Massachusetts General Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    lenalidomide • cytarabine • etoposide IV • mitoxantrone • Depocyte (liposomal cytarabine)
    9ms
    An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1/2, N=70, Terminated, Kartos Therapeutics, Inc. | Phase classification: P1b/2 --> P1/2 | Trial completion date: Jul 2024 --> Sep 2023 | Active, not recruiting --> Terminated; In September 2023, the study was terminated because of a Sponsor decision, unrelated to safety concerns.
    Phase classification • Trial completion date • Trial termination • Combination therapy
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    cytarabine • decitabine • navtemadlin (KRT-232) • Depocyte (liposomal cytarabine)
    11ms
    Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P2, N=11, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    cytarabine • cyclophosphamide • decitabine • clofarabine • idarubicin hydrochloride • fludarabine IV • busulfan • Depocyte (liposomal cytarabine)
    11ms
    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P2, N=160, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    cytarabine • decitabine • cladribine • Depocyte (liposomal cytarabine)
    11ms
    NCI-2022-03803: A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts (clinicaltrials.gov)
    P2, N=60, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • cladribine • Depocyte (liposomal cytarabine)
    11ms
    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P2, N=160, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
    Trial completion date • Trial primary completion date
    |
    cytarabine • decitabine • cladribine • Depocyte (liposomal cytarabine)
    12ms
    Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=26, Active, not recruiting, Medical College of Wisconsin
    Trial completion date • Combination therapy
    |
    CD33 positive
    |
    cytarabine • mitoxantrone • Actimab-A (lintuzumab-Ac225) • Depocyte (liposomal cytarabine)
    1year
    Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=26, Active, not recruiting, Medical College of Wisconsin | Trial primary completion date: Oct 2024 --> May 2024
    Trial primary completion date • Combination therapy
    |
    CD33 positive
    |
    cytarabine • mitoxantrone • Actimab-A (lintuzumab-Ac225) • Depocyte (liposomal cytarabine)
    1year
    Auto Stem Cell Transplant for Lymphoma Patients (clinicaltrials.gov)
    P2, N=150, Recruiting, Masonic Cancer Center, University of Minnesota | Trial primary completion date: Sep 2023 --> Sep 2025
    Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • CD4 (CD4 Molecule) • TCL1A (TCL1 Family AKT Coactivator A)
    |
    ALK positive
    |
    cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Depocyte (liposomal cytarabine) • Neupogen (filgrastim)
    1year
    O-ICE: Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (clinicaltrials.gov)
    P2, N=25, Recruiting, New York Medical College | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    carboplatin • Gazyva (obinutuzumab) • ifosfamide • etoposide IV • Depocyte (liposomal cytarabine)
    over1year
    An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1b/2, N=86, Active, not recruiting, Kartos Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    cytarabine • decitabine • navtemadlin (KRT-232) • Depocyte (liposomal cytarabine)
    2years
    O-ICE: Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (clinicaltrials.gov)
    P2, N=25, Recruiting, New York Medical College | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    carboplatin • Gazyva (obinutuzumab) • ifosfamide • etoposide IV • Depocyte (liposomal cytarabine)
    3years
    Treatment for Advanced B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=45, Completed, New York Medical College | Recruiting --> Completed | N=24 --> 45 | Trial completion date: Dec 2019 --> Jun 2021
    Clinical • Trial completion • Enrollment change • Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • Depocyte (liposomal cytarabine)
    over3years
    O-ICE: Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (clinicaltrials.gov)
    P2, N=25, Recruiting, New York Medical College | Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Dec 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    carboplatin • Gazyva (obinutuzumab) • ifosfamide • etoposide IV • Depocyte (liposomal cytarabine)
    over3years
    An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1b/2, N=86, Recruiting, Kartos Therapeutics, Inc. | N=160 --> 86
    Clinical • Enrollment change • Combination therapy
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    cytarabine • decitabine • navtemadlin (KRT-232) • Depocyte (liposomal cytarabine)
    almost5years
    CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Jun 2019 --> Jun 2020
    Clinical • Trial primary completion date
    |
    CD19 (CD19 Molecule) • IL2 (Interleukin 2)
    |
    cytarabine • etoposide IV • carmustine • melphalan • Proleukin (aldesleukin) • Depocyte (liposomal cytarabine)